Novo Nordisk A/S

NYSE:NVO

Drug Manufacturers - General

Healthcare
$39.43 -1.09%

-$0.48 today

Market cap
$173.82B
Beta
0.35
P/E (TTM)
10.2
EPS (TTM)
$27.45
Dividend yield
4.18%
52W Low $35.12High $74.38

Volume 16.12M

Average 16.05M

NVO Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

Novo Nordisk A/SNYSE: NVO

Other Non-Cash Items · Q2 FY2026 · quarter ended Jun 2026

Other non-cash items turns positive

Q2 FY2026 other non-cash items was DKK 4.7B, compared with -DKK 2.61B a year earlier. Trailing-twelve-month other non-cash items was -DKK 38.4B.

Context

  • Other non-cash items amounted to 12.0% of revenue in FY2025, up 1.6 pp from a year earlier.
  • Other non-cash items increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other non-cash items holds near DKK 4.7B or moves back toward the trailing-twelve-month quarterly average of -DKK 9.6B.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
DKK 4.7B+156.0% QoQ
Last fiscal yearDec 2025
-DKK 37.16B+23.0% YoY
LTMJun 2026
-DKK 38.4B+48.1% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+280.3%——
1 year+23.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

DKK · from the cash flow

Latest · FY2025
(37.16B) DKK
Year-over-year change
-23.0%

Other Non-Cash Items vs competitors

How NVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +48.1% is the 6th highest of 10, against a peer median of +142.8%.
  • Other non-cash items amounts to 11.7% of revenue for NVO, versus a peer median of 9.0%.
NVO Competitors
Other Non-Cash Items for NVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 38.4B DKK+48.1%—11.7%
JNJJohnson & JohnsonLTM Sep 2026$18.01B USD+215.6%-60.9%18.1%
MRKMerck & Co., Inc.LTM Jun 2026$11.51B USD+218.4%-38.7%17.3%
ABBVAbbVie Inc.LTM Jun 2026$8.47B USD-18.7%+11.8%13.2%
PFEPfizer Inc.LTM Jun 2026$6.02B USD+249.4%+199.1%9.5%
SNYSanofiLTM Jun 2026€4.41B EUR+142.8%+27.7%9.0%
LLYEli Lilly and CompanyLTM Jun 2026$4.1B USD-23.3%+27.1%5.2%
AZNAstraZeneca PLCLTM Sep 2026$1.95B USD-885.8%-49.4%3.1%
GSKGSK plcLTM Jun 2026£1.69B GBP+310.1%—5.1%
AMGNAmgen Inc.LTM Jun 2026$392M USD-42.6%—1.0%
Peer median (excluding NVO) —+142.8%+11.8%9.0%

Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

DKK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income47.76B55.53B83.68B100.99B102.43B
Depreciation & Amortization6.03B7.36B9.41B19.11B21.98B
Deferred Income Tax11.32B13.54B20.99B26.2B28.11B
Stock-Based Compensation1.04B1.54B2.15B2.29B0
Change in Working Capital(8.66B)(5.54B)(12.25B)2.59B3.74B
Accounts Receivables(12.91B)(10.82B)(14.21B)(14.31B)0
Inventory(1.09B)(4.77B)(7.42B)(9.04B)0
Accounts Payables3.15B6.72B10.02B3.24B0
Other Working Capital2.19B3.34B(631M)22.7B3.74B
Other Non-Cash Items(2.49B)6.46B4.92B(30.21B)(37.16B)
Operating Cash Flow55B78.89B108.91B120.97B119.1B
Capital Expenditures(7.39B)(14.75B)(38.9B)(51.31B)(90.11B)
Acquisitions (Net)(18.28B)(7.08B)0(82.16B)1B
Purchases of Investments(7.11B)(9.74B)(13.29B)(19.81B)(723M)
Sales of Investments1.17B6.65B8.29B24.39B10.67B
Other Investing Activities4M(2.61B)(13.09B)(4.15B)(29.97B)
Investing Cash Flow(31.61B)(24.92B)(43.89B)(128.9B)(79.16B)
Debt Repayment15.47B(2.41B)(1.47B)73.06B24.74B
Common Stock Issued00000
Common Stock Repurchased(19.45B)(24.09B)(29.92B)(20.18B)(1.39B)
Dividends Paid(21.52B)(25.3B)(31.77B)(44.14B)(51.76B)
Other Financing Activities00000
Financing Cash Flow(25.49B)(51.8B)(63.16B)8.74B(28.41B)
Effect of Forex Changes591M(238M)(119M)455M(727M)
Net Change in Cash(1.51B)1.93B1.74B1.26B10.81B
Free Cash Flow47.62B64.13B70.01B69.66B28.99B

Novo Nordisk A/S

NYSE:NVO

Intrinsic Alpha fair value

Locked

Current Price

$39.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.